Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes.
OBJECTIVE: To explore prevalent metformin use as a potential moderator of the cardiovascular effects of dipeptidyl peptidase 4 inhibitors (DPP-4i). RESEARCH DESIGN AND METHODS: We performed a meta-analysis of the three major cardiovascular outcomes trials examining DPP-4i. We used meta-regression to examine how the cardiovascular effects of DPP-4i differ between prevalent metformin users and baseline nonusers. RESULTS: While prevalent metformin users experienced a trend toward improved cardiovascular outcomes with DPP-4i (summary hazard ratio [HR] 0.92 [95% CI 0.84, 1.01]), baseline metformin nonusers showed a trend toward harm (HR 1.10 [95% CI 0.97, 1.26]). The difference in overall DPP-4i effect between metformin user and nonuser subgroups was statistically significant (P = 0.036). CONCLUSIONS: Baseline metformin status may have a moderating effect on cardiovascular outcomes with DPP-4i use. This hypothesis-generating analysis suggests there is residual uncertainty as to how DPP-4i affect cardiovascular outcomes, depending on concurrently prescribed medications.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Treatment Outcome
- Proportional Hazards Models
- Metformin
- Humans
- Endocrinology & Metabolism
- Drug Interactions
- Dipeptidyl-Peptidase IV Inhibitors
- Diabetes Mellitus, Type 2
- 42 Health sciences
- 32 Biomedical and clinical sciences
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Treatment Outcome
- Proportional Hazards Models
- Metformin
- Humans
- Endocrinology & Metabolism
- Drug Interactions
- Dipeptidyl-Peptidase IV Inhibitors
- Diabetes Mellitus, Type 2
- 42 Health sciences
- 32 Biomedical and clinical sciences